Featured Research

from universities, journals, and other organizations

Denosumab treatment for postmenopausal osteoporosis increases bone density

Date:
June 23, 2014
Source:
Endocrine Society
Summary:
Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. Osteoporosis is a long-term disease that occurs when the creation of new bone doesn't keep up with the removal of old bone. The disorder primarily affects women past menopause, causing their bones to become weak and brittle, sometimes so much so that a fall or even a cough can cause a fracture.

Postmenopausal women with osteoporosis who take denosumab long-term have increased bone density, sustained low rate of fractures, and a favorable benefit/risk profile, a new multinational study finds. The results were presented Sunday, June 22, at ICE/ENDO 2014, the joint meeting of the International Society of Endocrinology and the Endocrine Society in Chicago.

"This study provides reassurance to physicians and their patients that long-term treatment with denosumab for at least 8 years leads to significant increases in bone density and is safe for appropriately selected women with postmenopausal osteoporosis," said lead study author E. Michael Lewiecki, MD, clinical assistant professor of medicine at the University of New Mexico School of Medicine in Albuquerque. "It's important to note that the overall risk of side effects did not increase over time."

Osteoporosis is a long-term disease that occurs when the creation of new bone doesn't keep up with the removal of old bone. The disorder primarily affects women past menopause, causing their bones to become weak and brittle, sometimes so much so that a fall or even a cough can cause a fracture. The treatments that reduce fracture risk by increasing bone density have important long-term effects.

This study showed that long-term treatment with denosumab was safe and resulted in continuing increases in bone density over the 8 years of treatment, with persistently low fracture rates.

To evaluate the long-term efficacy and safety of denosumab for up to 10 years, Dr. Lewiecki and his colleagues conducted the ongoing multinational FREEDOM clinical trial. In this study, the researchers present data from up to 8 years of continued denosumab treatment.

Among the almost 8,000 women originally enrolled in the FREEDOM trial, denosumab reduced their risk of vertebral fractures by 68%, reduced their risk of hip fractures by 40%, and reduced their risk of nonvertebral fractures by 20%, compared with placebo. The women taking the drug had no increase in their overall risk of cancer, infection, cardiovascular disease, delayed fracture healing, or hypocalcemia.

All the roughly 3,000 women in this long-term extension of the trial took denosumab for up to 8 years, and overall, they showed a continued increase in their mean bone mineral density, with a cumulative 8-year gain of 18.4% at the lumbar spine and 8.3% at the total hip, with few fractures and a good safety profile.


Story Source:

The above story is based on materials provided by Endocrine Society. Note: Materials may be edited for content and length.


Cite This Page:

Endocrine Society. "Denosumab treatment for postmenopausal osteoporosis increases bone density." ScienceDaily. ScienceDaily, 23 June 2014. <www.sciencedaily.com/releases/2014/06/140623091953.htm>.
Endocrine Society. (2014, June 23). Denosumab treatment for postmenopausal osteoporosis increases bone density. ScienceDaily. Retrieved October 20, 2014 from www.sciencedaily.com/releases/2014/06/140623091953.htm
Endocrine Society. "Denosumab treatment for postmenopausal osteoporosis increases bone density." ScienceDaily. www.sciencedaily.com/releases/2014/06/140623091953.htm (accessed October 20, 2014).

Share This



More Health & Medicine News

Monday, October 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Microneedle Patch Promises Painless Pricks

Microneedle Patch Promises Painless Pricks

Reuters - Innovations Video Online (Oct. 18, 2014) Researchers at The National University of Singapore have invented a new microneedle patch that could offer a faster and less painful delivery of drugs such as insulin and painkillers. Video provided by Reuters
Powered by NewsLook.com
Raw: Nurse Nina Pham Arrives in Maryland

Raw: Nurse Nina Pham Arrives in Maryland

AP (Oct. 17, 2014) The first nurse to be diagnosed with Ebola at a Dallas hospital walked down the stairs of an executive jet into an ambulance at an airport in Frederick, Maryland, on Thursday. Pham will be treated at the National Institutes of Health. (Oct. 16) Video provided by AP
Powered by NewsLook.com
Raw: Cruise Ship Returns to US Over Ebola Fears

Raw: Cruise Ship Returns to US Over Ebola Fears

AP (Oct. 17, 2014) A Caribbean cruise ship carrying a Dallas health care worker who is being monitored for signs of the Ebola virus is heading back to Texas, US, after being refused permission to dock in Cozumel, Mexico. (Oct. 17) Video provided by AP
Powered by NewsLook.com
Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

Spanish Govt: Four Suspected Ebola Cases in Spain Test Negative

AFP (Oct. 17, 2014) All four suspected Ebola cases admitted to hospitals in Spain on Thursday have tested negative for the deadly virus in a first round of tests, the government said Friday. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins